Clinical TrialsUpdated results from the Phase 1 trial evaluating PRT3789 in biomarker-selected SMARCA4-mutated cancers are expected to be a catalyst.
Financial PerformancePrelude Therapeutics shares represent a unique investment opportunity, with a potential upside of 646%.
Financial PositionPrelude ended 2024 with roughly $133.6M in cash, cash equivalents, and marketable securities, which should be sufficient to provide an operational runway into 2Q26.